A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
This research study is looking into a new medication called lepodisiran. The main goal is to find out if this medicine can help reduce the build-up of fatty deposits, known as plaque, in the arteries that supply blood to the heart. This study is for adults aged between 45 and 80 who have high levels of a specific type of cholesterol called Lipoprotein(a), or Lp(a), and who have either already experienced heart-related issues or are considered to be at a high risk of developing them. The study will compare lepodisiran to a dummy medicine (placebo) and will use special imaging techniques to observe any changes in these plaques. Taking part would last approximately 120 weeks.
Överblick
Vad handlar denna studie om?
This research study aims to understand if a new medication called lepodisiran can help people with high levels of Lipoprotein(a), often shortened to Lp(a). Lp(a) is a specific kind of cholesterol in your blood that, when elevated, can increase your chances of developing heart disease. Currently, there aren't many widely available treatments specifically designed to lower Lp(a), so this study is an important step in exploring new options.
The main focus of the study is to see how lepodisiran affects the fatty deposits, also known as plaque, that can build up inside your heart's arteries. These plaques can narrow the arteries and lead to serious heart problems. Researchers will compare lepodisiran against a 'placebo' – a dummy medicine that looks the same but contains no active drug. This allows them to clearly see if any changes are due to lepodisiran itself. They'll use a special type of X-ray scan called a Coronary Computed Tomography Angiography (CCTA) to get detailed pictures of your heart's blood vessels and carefully measure this plaque.
By participating, you would be helping medical science learn more about Lp(a) and how to better manage heart disease risk for people with high levels. The information gathered from this study could potentially lead to new treatments that improve the health and well-being of many people in the future.
Viktiga punkter
- The study tests a new medicine, lepodisiran, for high Lp(a) and heart artery plaque.
- It's for adults 45-80 with high Lp(a) who have heart disease or are at high risk.
- Lp(a) is a type of cholesterol that can increase your heart disease risk.
- Researchers will use special scans (CCTA) to observe changes in plaque.
- Participation lasts about 2.5 years and involves regular clinic visits and tests.
- You might receive the new medicine or a dummy medicine (placebo).
Vem kan vara berättigad?
To join this study, you would need to be aged between 45 and 80 years old. A key requirement is having a confirmed high level of a specific type of cholesterol called Lp(a) in your blood. You also need to have either already experienced heart-related problems, such as a heart attack, or be considered at a high risk of having one for the first time. We'd also need to see evidence of narrowing in your heart's arteries through a special scan, even if you don't have symptoms. If you're currently taking medicines to lower your cholesterol, like statins, these would need to have been at a steady dose for at least eight weeks before you join the study.
There are certain reasons why you might not be able to participate. For example, if you've had a recent major heart health event within the last two months, or if you have uncontrolled high blood pressure. Severe kidney or heart failure would also exclude you. If you've had certain heart surgeries in the past, or are planning any heart procedures during the study period, you wouldn't be able to take part. Also, if you can't safely have the special CCTA scan, perhaps due to allergies to the dye used or other medical reasons, you wouldn't be eligible. The team will carefully check all these details with you.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Är du mellan 45 och 80 år gammal?
- Do you have high levels of Lp(a) cholesterol?
- Have you experienced heart problems, or are you at high risk for them?
- Are you able to have a special heart scan called a CCTA?
- Do you have stable doses for any cholesterol-lowering medicines you take?
- Have you avoided major heart-related events in the last 2 months?
Vad innebär deltagande?
If you decide to take part in this study, your involvement would last for approximately 120 weeks, which is about two and a half years. During this time, you would receive either the new study medicine, lepodisiran, or a placebo (a dummy medicine). You wouldn't know which one you're receiving, nor would the study team, to ensure the results are as unbiased as possible. You would have regular visits to the clinic for various assessments, which will include blood tests to check your Lp(a) levels and overall health, and regular physical examinations. A key part of the study involves having special heart scans (CCTA) at specific times to monitor the fatty deposits in your arteries. You'd also be asked about your health and any side effects you might experience. All these assessments are designed to carefully track your progress and see how the study medicine is working.
Potentiella risker och fördelar
Platser (57)
- UCSD - Altman Clinical and Translational Research Institute (ACTRI)Verifierat postnummerLa Jolla, USA· Rekrytering
- Valley Kliniska Prövningar, Inc.Verifierat postnummerNorthridge, USA· Rekrytering
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterVerifierat postnummerTorrance, USA· Rekrytering
- Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine CareVerifierat postnummerFort Lauderdale, USA· Rekrytering
- Jacksonville Center for Clinical ResearchVerifierat postnummerJacksonville, USA· Rekrytering
- Merritt Island Medical Research, LLCVerifierat postnummerMerritt Island, United States· Rekrytering
- Inpatient Research ClinicVerifierat postnummerMiami Lakes, USA· Rekrytering
- Clinical Site Partners, LLC dba Flourish ResearchVerifierat postnummerWinter Park, USA· Rekrytering
- High Desert Heart & VascularVerifierat postnummerMeridian, United States· Rekrytering
- Massachusetts General HospitalVerifierat postnummerBoston, USA· Rekryterar inte ännu
- Profound Research LLCVerifierat postnummerFarmington Hills, United States· Rekrytering
- Vector Clinical TrialsVerifierat postnummerLas Vegas, USA· Rekrytering
Vanliga frågor
What is Lp(a) and why is it important?
Lp(a) is a type of fat and protein particle in your blood. High levels can increase your risk of heart disease by contributing to fatty build-up in your arteries.
Vad är en placebo?
A placebo is a 'dummy' treatment that looks just like the real medicine but contains no active drug. It helps researchers compare the effects of the active medicine fairly.
What is a CCTA scan?
A CCTA scan is a special type of X-ray that takes detailed pictures of the arteries around your heart to look for fatty deposits (plaque).
Kommer jag att veta om jag får den riktiga medicinen eller placebo?
No, neither you nor the study doctors will know whether you are receiving lepodisiran or the placebo during the study. This helps ensure unbiased results.
Hur länge varar studien?
If you take part, your involvement in the study will last for approximately 120 weeks, which is about two and a half years.
Hur du får reda på mer
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Intresserad av att delta?
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.